Vicente
Soriano Vazquez
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicacións en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (4)
2013
-
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-Week results of the VIKING study
Journal of Infectious Diseases, Vol. 207, Núm. 5, pp. 740-748
2011
-
European recommendations for the clinical use of HIV drug resistance testing: 2011 update
AIDS Reviews, Vol. 13, Núm. 2, pp. 77-108
2009
-
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): A randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance
Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 398-410
2004
-
Updated European recommendations for the clinical use of HIV drug resistance testing
Antiviral Therapy, Vol. 9, Núm. 6, pp. 829-848